ReviewGeroScience2024
Sarcopenia: no consensus, no diagnostic criteria, and no approved indication-How did we get here?
Review in GeroScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- The association between muscle mass and change in physical functioning in older adults: a systematic review and meta-analysis of prospective studies.European geriatric medicine · 2025Pooled it
- Acute Sarcopenia: Systematic Review and Meta-Analysis on Its Incidence and Muscle Parameter Shifts During Hospitalisation.Journal of cachexia, sarcopenia and muscle · 2025Pooled it
- Effects of exercise with or withoutFrontiers in nutrition · 2024Pooled it
- Trial
- Monitoring handgrip strength to motivate lifestyle choices for patients with diabetes type 2 - a pragmatic randomised controlled trial.Scandinavian journal of primary health care · 2024Trial
- Inotodiol prevents age-related muscle wasting by restoring mitochondrial function through liver X receptor beta signaling.Signal transduction and targeted therapy · 2026Article
- Design, Synthesis, and Biological Evaluation of Novel ML-167 Analogues as Therapeutic Candidates Against Sarcopenia-Induced Muscle Wasting.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Examining the relationship between D3Cr muscle mass, physical performance, and functional limitation in postmenopausal women.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Review
- Glycated Hemoglobin, Lifestyle, and Sarcopenia in Rural Older Adults: A Cross-Sectional Analysis.Nursing & health sciences · 2026Article
- Identification of Isoliensinine as a Novel CCR5 Inhibitor for the Prevention of Skeletal Muscle Atrophy Through Virtual Screening and Experimental Validation.Molecules (Basel, Switzerland) · 2026Article
- Sex-specific circadian and behavioral phenotypes in aged growth hormone receptor knockout mice.GeroScience · 2026Article
- Myokines in exercise‑mediated bone homeostasis: Molecular signaling mechanisms and therapeutic implications for bone disorders (Review).International journal of molecular medicine · 2026Review
- A three-biomarker panel for frailty prediction and risk stratification in institutionalized older adults: a multicenter validation study.European geriatric medicine · 2026Article
- Extracellular water may increase with age and be independently and negatively associated with muscle strength and physical function in older adults: A cross-sectional study.Physiological reports · 2026Article
- Active immunization against myostatin and activin A improves skeletal muscle performance in growth hormone-deficient mice.GeroScience · 2026Article
- Article
- Association of pectoralis major muscle cross-sectional area and mean density on chest CT with mortality in elderly COVID-19 patients: sex and side differences.BMC pulmonary medicine · 2026Article
- A prospective, single-center longitudinal study on the operational definition of sarcopenia in patients undergoing total knee arthroplasty.European geriatric medicine · 2026Article
- Signaling to make human ribosomes: Connections between the cytoplasm and the nucleolus.Molecular cell · 2026Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to the role of skeletal muscle in movement and locomotion, muscle plays a critical role in a broad array of metabolic processes that can contribute to improved health or risk of disease. The age-associated loss of muscle has been termed sarcopenia. The muscle is the primary site of insulin-stimulated glucose disposal and the largest component of basal metabolic rate, directly and indirectly affects bone density, produces myokines with pleiotropic effect on muscle and other tissues including the brain, and stores essential amino acids essential for the maintenance of protein synthesis during periods of reduced food intake and stress. As such, not surprisingly deterioration of skeletal muscle health, typically operationalized as decline of muscle mass and muscle strength is both a powerful risk factor and main consequence of chronic diseases, disability, and loss of independence, and it is one of the strongest risk factors for mortality. However, skeletal muscle remains one of the most plastic of all tissues, with rapid changes in rates of protein synthesis and degradation in response to physical activity and inactivity, inflammation, and nutritional and hormonal status. This has made the development of pharmacological therapies to increase muscle mass (or prevent loss), an important goal for decades. However, while remarkable advances in the understanding of molecular and cellular regulation of muscle protein metabolism have occurred recently, there are no approved drugs for the treatment of sarcopenia, the loss of skeletal muscle affecting millions of older people. The goal of this paper is to describe the possible reasons for the lack of new and effective pharmacotherapies to treat one of the most important risk factors for age-associated disease and loss of independence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.